Elgethun Capital Management Purchases 56 Shares of Eli Lilly and Company (NYSE:LLY)

Elgethun Capital Management raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,690 shares of the company’s stock after acquiring an additional 56 shares during the quarter. Eli Lilly and Company comprises approximately 4.6% of Elgethun Capital Management’s holdings, making the stock its 3rd largest position. Elgethun Capital Management’s holdings in Eli Lilly and Company were worth $19,061,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Rathbones Group PLC boosted its stake in Eli Lilly and Company by 20.9% during the 4th quarter. Rathbones Group PLC now owns 189,746 shares of the company’s stock valued at $146,484,000 after purchasing an additional 32,850 shares during the period. Twin Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 1.4% during the fourth quarter. Twin Capital Management Inc. now owns 18,310 shares of the company’s stock worth $14,136,000 after buying an additional 259 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in shares of Eli Lilly and Company by 17.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,350 shares of the company’s stock valued at $1,042,000 after acquiring an additional 200 shares during the period. Employees Retirement System of Texas grew its stake in shares of Eli Lilly and Company by 6.1% in the fourth quarter. Employees Retirement System of Texas now owns 205,168 shares of the company’s stock worth $158,390,000 after acquiring an additional 11,816 shares during the last quarter. Finally, Bell Asset Management Ltd bought a new position in Eli Lilly and Company during the fourth quarter worth $4,352,000. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on LLY. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research report on Friday, January 17th. Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 6.5 %

LLY stock opened at $737.56 on Monday. Eli Lilly and Company has a one year low of $692.96 and a one year high of $972.53. The stock has a market cap of $699.33 billion, a price-to-earnings ratio of 62.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a fifty day moving average price of $848.36 and a two-hundred day moving average price of $831.41. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.